My group applies methods of advanced genetic engineering of hematopoietic stem cells to develop novel adoptive cell therapies against cancer and maintains a parallel program of clinical development that maximizes the exchange between laboratory and bedside in the development of such therapies. We leverage strategies to target transgene expression to tumor-infiltrating myeloid cells and are collaborating with our Hi-TIDe colleagues, particularly the T cell systems engineering group and tumor microenvironment & biomarker discovery group, to use this platform to deploy therapeutic payloads within the tumor microenvironment that synergize with adoptive T cell therapies.